This report is bad news for DOWNRAMPERS. Great report for long term holders. Great report and great experienced management team. These guys down ramping are most probably controlling the bots on AJM shares.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress